Association of adipose tissue mediators with the development of cancer in patients with metabolic syndrome

The aim of the study was to summarize the available data on the relationship between adipose tissue mediators and cancer in patients with metabolic syndrome. Material and methods . A literature search was conducted using the PubMed and eliBRARY databases. Of the 400 articles published over the past...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Sibirskiĭ onkologicheskiĭ zhurnal 2024-05, Vol.23 (2), p.101-110
Hauptverfasser: Sereda, E. E., Chernyshova, A. L., Mamonova, T. Yu, Kakurina, G. V., Yunusova, N. V., Sidenko, E. A., Korshunov, D. A., Kondakova, I. V.
Format: Artikel
Sprache:eng ; rus
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The aim of the study was to summarize the available data on the relationship between adipose tissue mediators and cancer in patients with metabolic syndrome. Material and methods . A literature search was conducted using the PubMed and eliBRARY databases. Of the 400 articles published over the past 20 years, 58 studies were included in the review. Results . There is evidence of an unfavorable course of cancer in patients with metabolic syndrome that is explained by the presence of common pathogenetic pathways. In this review, special attention is paid to adipose tissue mediators that regulate the course of inflammation. The involvement of adipose tissue mediators in the pathogenesis of cancer is discussed. The relationship between adipokines of adipose tissue and the effects of specialized pro-resolving mediators (SpRM), which are metabolites of polyunsaturated fatty acids (resolvins, protectins and maresins), are considered. the associations of mediators that regulate the intensity of inflammation with the metabolic syndrome and cancer are discussed. Conclusion . Further studies will contribute to a better understanding of the relationship between metabolic syndrome and cancer and the search for adequate predictive markers to select the most effective drug strategy for correcting metabolic syndrome.
ISSN:1814-4861
2312-3168
DOI:10.21294/1814-4861-2024-23-2-101-110